Pathophysiological impact of diverse deregulation of tonic inhibition in Angelman syndrome
Dr. Kiyoshi Egawa from the Hokkaido University Graduate School of Medicine in Japan is conducting further research on Gaboxadol’s potential therapeutic affects in other parts of the AS brain, helping guide current and future clinical trials and move us closer to a cure.
AS research expert Dr. Ben Philpot says that “it’s critically important to do these types of pre-clinical studies to guide ongoing therapies and therapeutic trials. The hope is these additional studies, such as Dr. Egawa’s, will provide feedback so even better therapeutics are designed in the future.”
The ASF has funded two groundbreaking communications studies this year, each taking a unique approach to helping individuals with AS—no matter where they are on the communications spectrum—to better communicate their desires and needs.